Kitakaze Masatoshi, Hirao Motohiro, Miyamoto Atsushi, Hamakawa Takuya, Yamamoto Kazuyoshi, Nishikawa Kazuhiro, Maeda Sakae, Uemura Mamoru, Miyake Masakazu, Hama Naoki, Miyazaki Michihiko, Ikeda Masataka, Nakamori Shoji, Kiyokawa Hiroki, Mano Masayuki, Sekimoto Mitsugu
Dept. of Surgery, National Hospital Organization Osaka National Hospital.
Gan To Kagaku Ryoho. 2016 Nov;43(12):2237-2239.
The most frequent relapse site of gastrointestinal stromal tumors(GIST)is the liver. We encountered a patient with longterm survival treated with multidisciplinary treatment, including4 hepatectomies for liver metastases. The patient was a woman aged 69 years at the time of the first medical treatment. She underwent total gastrectomy and S6 segmental hepatec- tomy for a stomach GIST with a hepatic metastasis. The tumor diameter was 24 cm and the mitotic figure was 65/50 HPF. According to the guidelines, it was diagnosed as a high risk GIST based on strong positive immunostaining for CD34 and c-kit. The tumor had metastasized to the liver and greater omentum. She took imatinib in the year following surgery. Because the GIST had spread to the lung1 8 months after the operation, she took imatinib again. Two years after the operation the pulmonary metastasis showed a clinical complete response(cCR)and the CR lasted for 4 years. Six years after the surgery she had a hepatic recurrence in S5, and she underwent an S5/4 partial hepatic resection. Seven years after the first operation, a liver S7 metastasis developed and she underwent S7 partial hepatectomy. Ten years after the first surgery, the GIST relapsed in liver S6 with right adrenal gland permeation. She underwent partial S6/7 liver resection and a right adrenal gland resection. She resumed takingimatinib after this surgical resection. Now, 11 years after the first operation, she is alive with an S1 hepatic recurrence taking sunitinib. Therefore, multidisciplinary treatment with surgical resection prolongs the survival of patients with resectable liver metastases of GIST.
胃肠道间质瘤(GIST)最常见的复发部位是肝脏。我们遇到了一名接受多学科治疗后长期存活的患者,其中包括4次针对肝转移灶的肝切除术。该患者初次就诊时为69岁女性。她因胃GIST伴肝转移接受了全胃切除术和S6段肝切除术。肿瘤直径为24 cm,核分裂象为65/50高倍视野(HPF)。根据指南,基于CD34和c-kit免疫染色强阳性,诊断为高危GIST。肿瘤已转移至肝脏和大网膜。术后第一年她服用伊马替尼。由于术后18个月GIST扩散至肺部,她再次服用伊马替尼。术后两年肺转移灶出现临床完全缓解(cCR),且该完全缓解持续了4年。术后6年她在S5段出现肝复发,接受了S5/4部分肝切除术。首次手术后7年,肝脏S7段出现转移,她接受了S7部分肝切除术。首次手术后10年,GIST在肝脏S6段复发并侵犯右肾上腺。她接受了S6/7部分肝切除术和右肾上腺切除术。此次手术切除后她恢复服用伊马替尼。现在,首次手术后11年,她因肝脏S1段复发服用舒尼替尼,仍然存活。因此,手术切除的多学科治疗可延长可切除肝转移GIST患者的生存期。